Trials / Terminated
TerminatedNCT02718482
Phase II Trial for the Treatment of Relapsed Osteosarcoma
Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Italian Sarcoma Group · Network
- Sex
- All
- Age
- 4 Years
- Healthy volunteers
- Not accepted
Summary
Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma
Detailed description
Patients with relapsed osteosarcoma will be randomized to receive Gemcitabine plus Docetaxel or High Doses Ifosfamide (continuous infusion) every 3 weeks, up to 6 weeks
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine and Docetaxel | Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle |
| DRUG | Ifosfamide | Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle |
Timeline
- Start date
- 2016-04-06
- Primary completion
- 2019-01-07
- Completion
- 2019-01-07
- First posted
- 2016-03-24
- Last updated
- 2019-05-13
Locations
10 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02718482. Inclusion in this directory is not an endorsement.